Gout drug allopurinol may boost heart function in african americans with resistant hypertension

NCT ID NCT05888233

Ongoing Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether allopurinol, a common gout medication, can improve heart function in African American veterans with resistant hypertension. Participants take allopurinol for 8 weeks, and researchers measure changes in heart function, exercise ability, and quality of life. The trial involves 40 people in Birmingham, Alabama.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Allopurinol
What this could lead to: If it works, this could point toward a new way to improve heart function and quality of life for African Americans with resistant hypertension.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Allopurinol can cause side effects like rash or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure hypertensive disorder resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE PRESERVED EJECTION FRACTION RESISTANT HYPERTENSION

Contacts and locations

Locations

Birmingham VA Medical Center, Birmingham, AL

Birmingham, Alabama, 35233-1927, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.